Premium
P4‐463: SAVVY EXPRESS: A PILOT STUDY TO DETERMINE THE FEASIBILITY, ACCEPTABILITY, AND OUTCOMES OF A PSYCHEDUCATIONAL AND SKILL‐BUILDING INTERVENTION FOR CARE PARTNERS OF PERSONS LIVING WITH DEMENTIA
Author(s) -
Aranda Maria P.,
Cherry Debra L.
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.4135
Subject(s) - dementia , intervention (counseling) , psychosocial , psychology , anxiety , ethnically diverse , competence (human resources) , psychological intervention , clinical psychology , session (web analytics) , nursing , medicine , psychiatry , social psychology , population , environmental health , world wide web , computer science , disease , pathology
team medication therapy management intervention can reduce inappropriate medication use and augment CR in communitydwelling, non-demented elderly subjects. We are targeting the Beers 2015 list of PIM for adults 65 years and older and implementing individualized alternative management strategies. Primary outcome measures include preto post-intervention measures of inappropriate medications use (Medication Appropriateness Index [MAI]), and Cognitive Reserve Change Score (CRCS); CRCS is defined as the difference between scopolamine-challenged and unchallenged neurocognitive test measures. We are also quantifying baseline preclinical amyloid burden (total brain relative standardized uptake values [SUVr]) to evaluate its impact of on CR deficits and decline, as well on delaying symptomatic disease progression in pAD. Results: The study is currently recruiting. To date, we have enrolled 57 participants (goal: 90 participants), of whom 41 have completed all baseline evaluations, and18 have completed the study. The mean (SD) age at enrollment is 73 (5.5), 60% of the participants are women, and 20% are non-white, with a median (IQR) number of 2 (1-4) PIM at baseline, resulting in a median (IQR) MAI of 11 (5-17). 33% of the participants have global SUVr < 1.2, 30% range from 1.2 to < 1.4, and 37% have SUVr 1.4. The mean (SD) CRCS (based on CVLT immediate recall T-score) is 5.2 (7.6). Conclusions: We hypothesize that targeted reductions in inappropriate medication use will bolster CR in subjects at risk for AD, delaying the onset of clinical symptoms. The INCREASE study, while showing substantial progress with regard to participant enrollment and follow-up, is gathering valuable information for the proposed CRCS hypothesis.